1. Oral Immunotherapy With Human Secretory Immunoglobulin A Improves Survival in the Hamster Model of Clostridioides difficile Infection.
- Author
-
Chiari EF, Weiss W, Simon MR, Kiessig ST, Pulse M, Brown SC, Gerding HR, Mandago M, Gisch K, and von Eichel-Streiber C
- Subjects
- Animals, Cricetinae, Humans, Immunoglobulin A, Immunologic Factors, Anti-Bacterial Agents therapeutic use, Clostridioides difficile, Clostridium Infections therapy, Immunoglobulin A, Secretory therapeutic use, Immunotherapy methods, Vancomycin therapeutic use
- Abstract
Coadministration of human secretory IgA (sIgA) together with subtherapeutic vancomycin enhanced survival in the Clostridioides difficile infection (CDI) hamster model. Vancomycin (5 or 10 mg/kg × 5 days) plus healthy donor plasma sIgA/monomeric IgA (TID × 21 days) or hyperimmune sIgA/monomeric IgA (BID × 13 days) enhanced survival. Survival was improved compared to vancomycin alone, P = .018 and .039 by log-rank Mantel-Cox, for healthy and hyperimmune sIgA, respectively. Passive immunization with sIgA (recombinant human secretory component plus IgA dimer/polymer from pooled human plasma) can be administered orally and prevents death in a partially treated CDI hamster model., (© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF